Trial Profile
Dose Ranging Study to Evaluate the Safety and Efficacy of Mapracorat Ophthalmic Formulation, in Subjects With Allergic Conjunctivitis Compared to Vehicle in a Conjunctival Allergen Challenge (CAC).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2020
Price :
$35
*
At a glance
- Drugs Mapracorat (Primary)
- Indications Allergic conjunctivitis
- Focus Therapeutic Use
- Sponsors Bausch & Lomb
- 23 Dec 2014 New trial record